No results for ‘’
Lupin Ltd
₹2272.90
(0.38%)
Wed, 17 Jun 2026, 08:45 am
Health Technology
Pharmaceuticals: Other
24.5KLupin Debt to Equity Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 24.18 | 16.10 | 9.92 | 11.44 | 20.88 | 21.58 | 27.36 | 21.50 | 22.94 | 37.73 | 29.65 | 25.59 | 132.92 | 55.34 | 0 | 38.20 | 0 | 68.83 | 38.64 | 28.27 |
| Price to book ratio | 6.56 | 5.57 | 3.17 | 4.01 | 5.63 | 5.65 | 5.90 | 5.41 | 6.05 | 10.17 | 5.98 | 4.83 | 2.45 | 2.43 | 2.13 | 3.36 | 2.80 | 2.37 | 5.17 | 5.39 |
| Price to sales ratio | 2.42 | 2.43 | 1.50 | 1.52 | 3 | 3.26 | 3.41 | 2.99 | 3.80 | 7.20 | 4.86 | 3.85 | 2.15 | 2.33 | 1.76 | 3.09 | 2.08 | 1.80 | 3.76 | 4.17 |
| Price to cash flow ratio | 39.41 | 30.27 | 17.01 | 13.54 | 22.28 | 24.24 | 44.83 | 23.15 | 21.17 | 32.44 | 0 | 16.32 | 20.99 | 22.53 | 21.25 | 26.87 | 122.67 | 17.38 | 21.68 | 31.99 |
| Enterprise value | 4555Cr | 5368Cr | 4989Cr | 6900Cr | 15195Cr | 19403Cr | 25043Cr | 29017Cr | 41852Cr | 89043Cr | 73082Cr | 70578Cr | 38915Cr | 39010Cr | 28574Cr | 47542Cr | 36180Cr | 32490Cr | 74928Cr | 94105Cr |
| Enterprise value to EBITDA ratio | 19.58 | 17.75 | 10.63 | 6.34 | 17.12 | 17.91 | 18.24 | 13.36 | 14.37 | 24.78 | 19.50 | 16.54 | 6.54 | 16.57 | 13.06 | 18.52 | 17.19 | 19.42 | 21.11 | 19.31 |
| Debt to equity ratio | 1.49 | 0.99 | 0.94 | 0.86 | 0.44 | 0.35 | 0.41 | 0.22 | 0.09 | 0.06 | 0.64 | 0.59 | 0.53 | 0.62 | 0.53 | 0.37 | 0.34 | 0.37 | 0.20 | 0.32 |
| Return on equity % | 30.47 | 40.55 | 37.92 | 37.09 | 34.14 | 29.50 | 23.80 | 28.52 | 30.27 | 30.41 | 22.57 | 20.74 | 1.86 | 3.75 | -3.04 | 9.24 | -11.79 | 3.50 | 14.34 | 20.88 |
Lupin Ltd Debt to Equity Ratio
The Lupin Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate Lupin Ltd's valuation, profitability, and overall financial performance. Tracking the Lupin Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Lupin Ltd (NSE: LUPIN, BSE: 500257) is currently trading at ₹2272.90, with a market capitalization of ₹102992.45Cr. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Lupin Ltd Debt to Equity Ratio is essential for fundamental analysis.
Lupin Ltd Debt to Equity Ratio Current Value
The current Lupin Ltd Debt to Equity Ratio stands at 0.32.
The latest Lupin Ltd Debt to Equity Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Lupin Ltd Debt to Equity Ratio Historical Trend
The Lupin Ltd Debt to Equity Ratio has shown the following historical trend:
- 2024: 0.32
- 2023: 0.20
- 2022: 0.37
- 2021: 0.34
- 2020: 0.37
The recent rise in Lupin Ltd Debt to Equity Ratio suggests strengthening valuation trends and improving market sentiment.
What Lupin Ltd Debt to Equity Ratio Indicates for Investors
The Lupin Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
Lupin Ltd Debt to Equity Ratio Analysis Summary
The Lupin Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Lupin Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Lupin Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.